News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PX’Therapeutics Licenses ribOvax Biotechnologies SA (Ribovax)'s SEBVI Technology for the Development and Manufacturing of Fully Human Monoclonal Antibodies


7/27/2011 8:51:14 AM

GRENOBLE, France--(BUSINESS WIRE)--PX’Therapeutics SA (PX’T) and ribOvax Biotechnologies SA (Ribovax) have announced that they have entered into a licensing agreement to provide PX’T with access to Ribovax’s patented SEBVI Technology for the discovery and development of antibodies of entirely human origin.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES